

Development of novel small molecule antiviral therapeutics for pathogens with epidemic potential

Horizon Europe

● PENDENTE

Código

HORIZON-HLTH-2027-01-DISEASE-05

Âmbito

Internacional

Localização

Europa

Curadoria

Marlene Faria

DETALHES FINANCEIROS

Tipo de apoio

Fundo Perdido

Taxa Máxima de Financiamento

100%

Dotação

44.2M€

Valor Elegível do Projeto

9M€ - 11M€

DATAS E PRAZOS

Data de Publicação

Não definida

Data de Abertura

29 de outubro de 2026

Fase única

17 de fevereiro de 2027 às 17:00 GMT+1

DESCRIÇÃO

Objectives

This topic aims to advance the development of novel or existing small-molecule antiviral candidates for the prevention and treatment of emerging and re-emerging viral infections. It seeks to expand therapeutic options that can be rapidly deployed during future epidemics or pandemics, strengthen European preparedness and reinforce the EU's leadership in antiviral research and development, in line with the European Medical Countermeasures Strategy. Antibodies and antibody-derived proteins are outside the scope of this topic.

Funding

Funding is provided under a Horizon Europe Research and Innovation Action (RIA). The topic has an indicative budget of €44.2 million, with approximately five projects expected to be funded. The anticipated

EU contribution ranges from €9 million to €11 million per project, although proposals requesting different amounts may be considered where appropriately justified. RIAs may receive funding of up to 100% of eligible costs, in accordance with Horizon Europe rules.

DESPESAS ELEGÍVEIS

- Personnel Costs
- Travel costs
- Equipment costs
- Other goods, works and services costs
- Subcontracting
- Indirect Costs
- Personnel
- Research infrastructure
- Equipment
- Consumables
- Travel
- Dissemination activities

ELEGIBILIDADE

Setores Elegíveis

Saúde & Ciências da Vida

Modalidade de Candidatura

Consórcio / Copromoção

Tipologia de Beneficiário

- Micro
- PME
- Small Mid-Cap
- Mid-Cap
- Grande
- Entidades não empresariais do sistema de I&I (ENESII)
- Entidades privadas sem fins lucrativos
- Entidades públicas

Tipos de Ação

- Research and Innovation Action
- Collaborative Health Research

DETALHES DO PROGRAMA UE

ID da Chamada	Cluster
HORIZON-HLTH-2027-01-DISEASE-05	Health
Destino	Modo de Submissão
D3. Tackling diseases and reducing disease burden	Single-stage
Contribuição UE	Projetos Esperados
Around €10,000,000.00 to €11,000,000.00 per project	5
Regra de Taxa de Financiamento	
Up to 100% of eligible costs for Research and Innovation Actions (RIA)	

LINKS OFICIAIS

Regulamento Oficial

<https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/HORIZON-HLTH-2027-01-DISEASE-05?order=DESC&pageNumber=1&pageSize=50&sortBy=startDate&keywords=HORIZON-HLTH-2027-01-DISEASE-05&isExactMatch=true&status=31094501,31094502,31094503>

Página no Grantavia

<https://grantavia.com/pt/incentives/development-of-novel-small-molecule-antiviral-therapeutics-for-pathogens-with-epidemic-potential>

Agendar reunião

<https://calendly.com/sandra-cardoso-epsa/reuniao>